Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ambys Medicines
South San Francisco, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
The company had demonstrated the ability to produce high-quality liver cells at scale that function in vivo as normal healthy liver cells. Their lead program was planned to enter clinical trials in 2023, but the company closed operations in February 2023[1].
- Therapeutic areas
- Gastroenterology
- Modalities
- Cell therapyAllogeneic cell therapy
- Industry
- Biotech
Beyond the preview
Go deeper on Ambys Medicines.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ambys Medicines.